# US 2011/0027316 A1 · Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0027316 A1
- Document ID: US20110027316A1
- Status: Published application
- Kind: A1
- Application number: 12/744,136
- Filed: 2008-11-21
- Published: 2011-02-03
- Earliest claimed: 2007-11-21
- Assignees: Wyeth Farma, S.A.
- Inventors: Joan Plana Duran
- Web page: https://patentgrep.com/patent/US20110027316A1

## CPC

- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 39/12: Viral antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- C12N 2720/12134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/12163: by chemical treatment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus.

## Claims

### Claim 1

A composition for eliciting an immune response against Bluetongue virus (BTV) in an animal, the composition comprising an immunogenically effective amount of at least one strain of a twice inactivated Bluetongue virus and a biologically acceptable adjuvant.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the twice inactivated BTV is inactivated a first time with an inactivating agent at a concentration of about 10 mM and inactivated a second time with an inactivating agent at a concentration of about 5 mM.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the inactivating agent is binary ethyleneimine (BEI).

### Claim 4 (depends on 1)

The composition of claim 1, wherein the strain is serotype 4.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein the animal is a ruminant selected from the group consisting of sheep, lambs, goats, cattle and deer.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein the biologically acceptable adjuvant comprises one or more of aluminum hydroxide, saponin, SL-CD, Carbopol and SP-Oil.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the biologically acceptable adjuvant comprises a mixture of aluminum hydroxide and saponin.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the aluminum hydroxide is present at a concentration of between about 1% and about 10%; between about 2% and about 5%; or at a concentration of about 3%.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The composition of claim 1, wherein the immune response elicited protects an animal against infection with, or reduces the severity of at least one symptom associated with an infection by a pathogenic strain of Bluetongue virus.

### Claim 14 (depends on 1)

A method for enhancing the immune response in an animal to Bluetongue virus, or for preventing or reducing at least one symptom associated with the disease, the method comprising the step of administering a single or multiple doses of the composition of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the animal is a ruminant selected from the group consisting of sheep, lambs, goats, cattle and deer.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The method of claim 14, wherein the step of administering is achieved by parenteral administration or oral administration.

### Claim 18 (depends on 17)

The method of claim 17, wherein the parenteral administration step is achieved by intramuscular injection.

### Claim 19

(canceled)

### Claim 20 (depends on 14)

The method of claim 14, wherein the oral administration step is achieved by hand delivery or mass application.

### Claim 21 (depends on 1)

A method of preventing or ameliorating an outbreak of Bluetongue virus, which comprises the step of administering to an animal a composition of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the animal is a ruminant selected from the group consisting of sheep, lambs, goats, cattle and deer.

### Claim 23

(canceled)

### Claim 24 (depends on 21)

The method of claim 21, wherein the step of administering is achieved by parenteral administration or oral administration.

### Claim 25 (depends on 24)

The method of claim 24, wherein the parenteral administration step is achieved by intramuscular injection.

### Claim 26

(canceled)

### Claim 27 (depends on 24)

The method of claim 24, wherein the oral administration step is achieved by hand delivery or mass application.

### Claim 28

A method of producing inactivated whole Bluetongue virus (BTV), the method comprising the steps of:
a) treating the BTV with an inactivating agent using a 1:10 ratio of inactivating agent to BTV;
b) homogenizing the inactivating agent/BTV mixture of step a) for at least 15 minutes;
c) decanting the mixture of step b) into a sterile container and agitating the mixture for about 24 hours;
d) treating the BTV a second time with an inactivating agent using a 1:20 ratio of inactivating agent to BTV;
e) homogenizing the inactivating agent/BTV mixture of step d) for at least 15 minutes;
f) decanting the mixture of step e) into a sterile container and agitating the mixture for about 48 hours; and
g) neutralizing the inactivating agent to adjust the final pH to about 7.2;
wherein the method results in inactivation of the BTV while maintaining the immunogenicity of the BTV.

### Claim 29 (depends on 28)

The method of claim 28, wherein the inactivating agent is binary ethyleneimine
(BEI).

### Claim 30 (depends on 28)

The method of claim 28, wherein the final concentration of inactivating agent in step a) is about 10 mM.

### Claim 31 (depends on 28)

The method of claim 28, wherein the final concentration of inactivating agent in step d) is about 5 mM.

### Claim 32 (depends on 28)

The method of claim 28, wherein the whole Bluetongue virus is serotype 4.
